Gabelli Funds LLC Buys 6,750 Shares of Mesa Laboratories, Inc. $MLAB

Gabelli Funds LLC raised its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 12.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 60,724 shares of the medical instruments supplier’s stock after purchasing an additional 6,750 shares during the quarter. Gabelli Funds LLC’s holdings in Mesa Laboratories were worth $4,767,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. CWM LLC lifted its stake in Mesa Laboratories by 48.9% during the 3rd quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 196 shares during the period. BNP Paribas Financial Markets lifted its stake in Mesa Laboratories by 115.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 421 shares during the period. Tower Research Capital LLC TRC lifted its stake in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after acquiring an additional 684 shares during the period. Brevan Howard Capital Management LP bought a new position in Mesa Laboratories during the 2nd quarter valued at about $217,000. Finally, Quantbot Technologies LP bought a new position in Mesa Laboratories during the 3rd quarter valued at about $178,000. Institutional investors own 90.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wells Fargo & Company upped their price target on shares of Mesa Laboratories from $83.00 to $94.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Mesa Laboratories in a research report on Monday, May 4th. Finally, Wall Street Zen raised shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $94.00.

Insider Buying and Selling

In other news, Director Shiraz Shabanali Ladiwala bought 3,500 shares of Mesa Laboratories stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average cost of $72.23 per share, with a total value of $252,805.00. Following the acquisition, the director owned 8,523 shares of the company’s stock, valued at $615,616.29. The trade was a 69.68% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark Christopher Capone bought 1,301 shares of Mesa Laboratories stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $76.35 per share, with a total value of $99,331.35. Following the completion of the acquisition, the director directly owned 3,429 shares in the company, valued at $261,804.15. This represents a 61.14% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 6,116 shares of company stock valued at $452,076. 4.90% of the stock is owned by corporate insiders.

Mesa Laboratories Price Performance

NASDAQ MLAB opened at $104.00 on Thursday. Mesa Laboratories, Inc. has a 52 week low of $55.45 and a 52 week high of $115.35. The firm has a market capitalization of $574.08 million, a P/E ratio of 162.50 and a beta of 0.94. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.86. The company has a 50-day moving average price of $93.27 and a 200-day moving average price of $86.53.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Friday, May 29th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 29th. Mesa Laboratories’s dividend payout ratio is currently 100.00%.

Mesa Laboratories Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.